Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Micro-RNA Expression Profiles in Localised Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03338712
Recruitment Status : Withdrawn (Principal Investigators no longer in business)
First Posted : November 9, 2017
Last Update Posted : November 9, 2017
Sponsor:
Information provided by (Responsible Party):
Wuerzburg University Hospital

Tracking Information
First Submitted Date November 2, 2017
First Posted Date November 9, 2017
Last Update Posted Date November 9, 2017
Estimated Study Start Date February 1, 2010
Estimated Primary Completion Date April 1, 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: November 6, 2017)
Recurrence free survival [ Time Frame: Up to 120 months. From date of inclusion until date of death from any cause ]
The patients will be followed in regular time intervals in accordance with the EAU-Guidelines (2010) and the S-3 Guideline for Prostate cancer of the German Urological Association.
Original Primary Outcome Measures Same as current
Change History No Changes Posted
Current Secondary Outcome Measures
 (submitted: November 6, 2017)
Cancer specific survival [ Time Frame: Up to 120 months. From date of inclusion until date of death from any cause ]
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Micro-RNA Expression Profiles in Localised Prostate Cancer
Official Title Micro-RNA Expression Profiles in Localised Prostate Cancer
Brief Summary Recurrence free survival The patients will be followed in regular time intervals in accordance with the EAU-Guidelines (2010) and the S-3 Guideline for Prostate cancer of the German Urological Association. Data will be updated once yearly for until death.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Not Provided
Condition
  • Prostate Cancer
  • Radical Prostatectomy
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Withdrawn
Actual Enrollment
 (submitted: November 6, 2017)
0
Original Actual Enrollment Same as current
Estimated Study Completion Date April 1, 2016
Estimated Primary Completion Date April 1, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • 35 Years to 80 Years
  • Male
  • Patients with clinically localised high risk prostate cancer

Exclusion Criteria:

-

Sex/Gender Not Provided
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers Not Provided
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT03338712
Other Study ID Numbers mi-RNA-PCa
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party Wuerzburg University Hospital
Study Sponsor Wuerzburg University Hospital
Collaborators Not Provided
Investigators Not Provided
PRS Account Wuerzburg University Hospital
Verification Date November 2017